Accn.Ns

ACCN.NS maintains a strong liquidity position with a current ratio of 5.08, indicating that its current assets significantly exceed its current liabilities. The company's liquidity_fpt metric shows a net cash position of INR 1,914,697,000, which is the result of total cash and equivalents minus total debt. This liquidity is supported by a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing.

Profitability metrics for ACCN.NS are robust, with a return on equity (ROE) of 33.95% and a return on assets (ROA) of 28.95%. These figures are well above the industry median for ROE and ROA in the Pharmaceuticals sector, indicating that the company is effectively utilizing its equity and asset base to generate returns. The operating margin of 28.95% also reflects strong cost control and pricing power.

Geographically, ACCN.NS is heavily concentrated in the Indian market, with the majority of its revenue derived from domestic operations. The company does not disclose significant international revenue in its latest financials, which may expose it to regulatory and macroeconomic risks specific to India. There is no detailed breakdown of revenue by product segment in the latest filings, but the company's focus is primarily on prescription drugs and R&D partnerships.

The company's growth trajectory is positive, with a year-over-year revenue increase of 12.3% in the most recent fiscal year. The outlook for the next fiscal year suggests a continuation of this trend, with a projected revenue growth of 8.5%. This growth is supported by a strong operating cash flow of INR 493,462,000 and a free cash flow of INR 314,074,000, which provides flexibility for reinvestment or shareholder returns.

Risk factors for ACCN.NS include regulatory scrutiny in the pharmaceutical sector and potential pricing pressures from government policies. The company's risk assessment indicates a medium liquidity risk, primarily due to the negative net cash position after subtracting total debt. While the dilution risk is currently low, the company has not issued new shares in the past 12 months, and there is no indication of dilution in the latest filings. The risk assessment also notes that the company's capital structure is stable, with a low debt burden and strong equity position.

Recent events include the filing of the latest annual report, which provides an updated overview of the company's financial performance and strategic direction. There are no recent earnings call transcripts or press releases indicating significant operational or strategic changes. The company continues to focus on R&D and product development, with no major acquisitions or divestitures reported in the past year.